Rossari Biotech Reports FY26 Net Profit of ₹14.92 Crore, Declares Dividend and Opens R&D Center

Rossari Biotech's Board of Directors has approved the audited financial results for the fiscal year ending March 31, 2026. The company announced consolidated revenue of ₹23,963.65 million (₹239.64 crore) and a consolidated net profit after tax of ₹1,492.13 million (₹14.92 crore).

A final dividend of Re 0.50 per equity share for FY2025-26 was declared. The company also allotted 8,250 equity shares under the Rossari Employee Stock Option Plan - 2019.

Innovation and Growth Strategy

The company has established a new Research and Development (R&D) facility in Navi Mumbai, reinforcing its commitment to innovation and the development of advanced chemical solutions. This move is crucial for maintaining competitiveness within the specialty chemicals market.

Concurrently, Rossari Biotech is re-evaluating capacity expansion projects for its material subsidiaries. These projects are now scheduled for phased implementation over the next two years, indicating a calibrated approach to capital investment in response to market dynamics.

Board Appointments and Governance

Udeypaul Singh Gill has been appointed as an Additional Director, Non-Executive, Independent, pending member approval. This appointment is expected to strengthen the board's governance and strategic oversight.

Company Background and Strategic Context

Rossari Biotech has historically prioritized R&D, operating dedicated research labs and focusing on sustainable product development. Strategic acquisitions, including Unitop Chemicals and Tristar Intermediates, have been key to expanding its product portfolio and market standing. The current adjustments to capacity expansion plans are an evolution of earlier announcements, now adapted for a phased rollout.

Legal and Financial Matters

In January 2026, Rossari Biotech concluded arbitration proceedings related to Unitop Chemicals. A tribunal directed the release of INR 97,90,617 as a tax refund, plus 12% annual interest and arbitration costs. The company has assessed the financial impact of this matter as limited and is considering its options.

Competitive Landscape

Rossari Biotech operates in the competitive specialty chemicals sector alongside peers such as Aarti Industries Ltd. and Vinati Organics Ltd. While Aarti Industries has demonstrated stronger historical sales growth and market capitalization, Vinati Organics has often achieved superior profit margins and return ratios. Rossari's strategic emphasis on R&D and diversification across segments like home and personal care, textiles, and animal health positions it to capitalize on evolving market demands.

Future Focus Areas

Key areas to monitor include:

• Shareholder approval for Udeypaul Singh Gill's appointment as Additional Director.
• The contribution and impact of the new Navi Mumbai R&D facility on future product pipelines.
• The execution and timeline adherence for phased capacity enhancement projects.
• The company's ability to adapt to changing market conditions affecting demand and investment strategies.